



## Clinical trial results:

### A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

#### Summary

EudraCT number	2011-002009-31
Trial protocol	CZ GB ES SK NL FR IT DE EE HU LV AT GR BG
Global end of trial date	27 September 2019

#### Results information

Result version number	v1 (current)
This version publication date	27 September 2020
First version publication date	27 September 2020

#### Trial information

##### Trial identification

Sponsor protocol code	MO25757
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01588184
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 March 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 September 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-trial) and who derived benefit from the therapy administered

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 July 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Brazil: 8
Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Czech Republic: 2
Country: Number of subjects enrolled	Estonia: 1
Country: Number of subjects enrolled	France: 9
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	Hungary: 1
Country: Number of subjects enrolled	Italy: 13
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 3
Country: Number of subjects enrolled	Mexico: 9
Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	Romania: 5
Country: Number of subjects enrolled	Russian Federation: 14
Country: Number of subjects enrolled	Slovakia: 1
Country: Number of subjects enrolled	South Africa: 1
Country: Number of subjects enrolled	Spain: 12
Country: Number of subjects enrolled	Sweden: 2
Country: Number of subjects enrolled	Turkey: 1

Country: Number of subjects enrolled	United Kingdom: 3
Worldwide total number of subjects	95
EEA total number of subjects	56

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	68
From 65 to 84 years	27
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The number of participants enrolled over the planned recruitment period was open. 95 participants actually enrolled in this study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Breast Cancer

Arm description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

<b>Arm title</b>	Ovarian Cancer or Peritoneal Carcinoma
------------------	--

Arm description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

<b>Arm title</b>	Colorectal Cancer
------------------	-------------------

Arm description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

<b>Arm title</b>	Renal Cell Carcinoma
------------------	----------------------

Arm description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

<b>Arm title</b>	Non-Squamous, Non-Small Cell Lung Cancer
------------------	--

Arm description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

<b>Arm title</b>	Glioblastoma Multiforme
------------------	-------------------------

Arm description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Arm type	Experimental
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

Number of subjects in period 1	Breast Cancer	Ovarian Cancer or Peritoneal Carcinoma	Colorectal Cancer
Started	11	41	7
Completed	8	28	5
Not completed	3	13	2
Adverse event, serious fatal	1	-	-
change in treatment	-	6	2
Consent withdrawn by subject	2	4	-
multiple reasons	-	3	-

Number of subjects in period 1	Renal Cell Carcinoma	Non-Squamous, Non-Small Cell Lung Cancer	Glioblastoma Multiforme
Started	6	16	14
Completed	3	14	10
Not completed	3	2	4
Adverse event, serious fatal	1	1	1
change in treatment	-	1	3
Consent withdrawn by subject	1	-	-
multiple reasons	1	-	-

## Baseline characteristics

### Reporting groups

Reporting group title	Breast Cancer
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Ovarian Cancer or Peritoneal Carcinoma
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Colorectal Cancer
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Renal Cell Carcinoma
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Non-Squamous, Non-Small Cell Lung Cancer
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Glioblastoma Multiforme
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	

Reporting group values	Breast Cancer	Ovarian Cancer or Peritoneal Carcinoma	Colorectal Cancer
Number of subjects	11	41	7
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	30	3
From 65-84 years	2	11	4
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	54.5	56.7	66.7
standard deviation	± 7.3	± 11.2	± 13.9
Sex: Female, Male Units:			
Female	11	41	3

Male	0	0	4
------	---	---	---

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	11	41	7

<b>Reporting group values</b>	Renal Cell Carcinoma	Non-Squamous, Non-Small Cell Lung Cancer	Glioblastoma Multiforme
Number of subjects	6	16	14
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	11	13
From 65-84 years	4	5	1
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	63.5	58.5	49.5
standard deviation	± 9.8	± 10.5	± 10.9
Sex: Female, Male			
Units:			
Female	2	6	4
Male	4	10	10
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	6	16	14

<b>Reporting group values</b>	Total		
Number of subjects	95		

Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	68		
From 65-84 years	27		
85 years and over	0		
Age Continuous Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male Units:			
Female	67		
Male	28		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0		
Asian	0		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	0		
White	0		
More than one race	0		
Unknown or Not Reported	95		

## End points

### End points reporting groups

Reporting group title	Breast Cancer
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Ovarian Cancer or Peritoneal Carcinoma
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Colorectal Cancer
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Renal Cell Carcinoma
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Non-Squamous, Non-Small Cell Lung Cancer
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	
Reporting group title	Glioblastoma Multiforme
Reporting group description: Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.	

### Primary: Percentage of Participants With Adverse Events

End point title	Percentage of Participants With Adverse Events <sup>[1]</sup>
End point description: An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.	
End point type	Primary
End point timeframe: Baseline up to approximately 81 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics only	

End point values	Breast Cancer	Ovarian Cancer or Peritoneal Carcinoma	Colorectal Cancer	Renal Cell Carcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	41	7	6
Units: percentage of participants				
number (not applicable)	90.9	78.0	71.4	100.0

<b>End point values</b>	Non-Squamous, Non-Small Cell Lung Cancer	Glioblastoma Multiforme		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	14		
Units: percentage of participants				
number (not applicable)	75.0	83.2		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
End point description:	Progression free survival is defined as the time from first dose of Bevacizumab in this extension trial (E-trial) to the time of first documented disease progression or death due to any cause, whichever occurs first.
End point type	Secondary
End point timeframe:	Baseline up to approximately 81 months

<b>End point values</b>	Breast Cancer	Ovarian Cancer or Peritoneal Carcinoma	Colorectal Cancer	Renal Cell Carcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	41	7	6
Units: months				
arithmetic mean (standard deviation)	35.31 (± 23.809)	24.39 (± 19.759)	17.98 (± 24.202)	9.31 (± 12.046)

<b>End point values</b>	Non-Squamous, Non-Small Cell Lung Cancer	Glioblastoma Multiforme		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	14		
Units: months				
arithmetic mean (standard deviation)	17.14 (± 14.152)	11.31 (± 10.301)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS)

End point title Overall Survival (OS)

End point description:

Overall survival time is defined as the time from first dose of Bevacizumab in this E-trial to death from any cause.

End point type Secondary

End point timeframe:

Baseline up to approximately 81 months

End point values	Breast Cancer	Ovarian Cancer or Peritoneal Carcinoma	Colorectal Cancer	Renal Cell Carcinoma
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	41	7	6
Units: months				
arithmetic mean (standard deviation)	38.82 (± 24.159)	27.35 (± 20.020)	20.30 (± 23.761)	11.98 (± 10.950)

End point values	Non-Squamous, Non-Small Cell Lung Cancer	Glioblastoma Multiforme		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	14		
Units: months				
arithmetic mean (standard deviation)	18.31 (± 14.962)	12.99 (± 10.795)		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to approximately 81 months

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	Breast Cancer
-----------------------	---------------

Reporting group description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Reporting group title	Colorectal Cancer
-----------------------	-------------------

Reporting group description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Reporting group title	Glioblastoma Multiforme
-----------------------	-------------------------

Reporting group description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Reporting group title	Non-Squamous, Non-Small Cell Lung Cancer
-----------------------	--

Reporting group description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Reporting group title	Ovarian Cancer or Peritoneal Carcinoma
-----------------------	--

Reporting group description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Reporting group title	Renal Cell Carcinoma
-----------------------	----------------------

Reporting group description:

Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

<b>Serious adverse events</b>	Breast Cancer	Colorectal Cancer	Glioblastoma Multiforme
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 11 (18.18%)	2 / 7 (28.57%)	3 / 14 (21.43%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
FEMUR FRACTURE			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>JAW FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
<b>AORTIC STENOSIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>CIRCULATORY COLLAPSE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPERTENSIVE CRISIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
<b>CARDIAC FAILURE</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SINUS BRADYCARDIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>ISCHAEMIC STROKE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>TRANSIENT ISCHAEMIC ATTACK</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ear and labyrinth disorders</b>			
<b>VERTIGO</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>VOMITING</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>PNEUMONITIS</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
<b>NEPHROTIC SYNDROME</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>APPENDICITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>COMPLICATED APPENDICITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MENINGITIS BACTERIAL</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>WOUND INFECTION</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>DEHYDRATION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Non-Squamous, Non-Small Cell Lung Cancer	Ovarian Cancer or Peritoneal Carcinoma	Renal Cell Carcinoma
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	5 / 16 (31.25%)	2 / 41 (4.88%)	3 / 6 (50.00%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events			
<b>Injury, poisoning and procedural complications</b>			
<b>FEMUR FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>JAW FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
<b>AORTIC STENOSIS</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>CIRCULATORY COLLAPSE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>HYPERTENSIVE CRISIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cardiac disorders</b>			
<b>CARDIAC FAILURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>SINUS BRADYCARDIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>ISCHAEMIC STROKE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>TRANSIENT ISCHAEMIC ATTACK</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Ear and labyrinth disorders</b>			
<b>VERTIGO</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>VOMITING</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>PNEUMONITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
<b>NEPHROTIC SYNDROME</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>APPENDICITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>COMPLICATED APPENDICITIS</b>			

alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>MENINGITIS BACTERIAL</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>WOUND INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>DEHYDRATION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Breast Cancer	Colorectal Cancer	Glioblastoma Multiforme
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 11 (90.91%)	5 / 7 (71.43%)	14 / 14 (100.00%)
Vascular disorders			

<p>EMBOLISM VENOUS</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>0 / 11 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>HYPERTENSION</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>2 / 11 (18.18%)</p> <p>occurrences (all)</p> <p>3</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>LYMPHOEDEMA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>Surgical and medical procedures</p> <p>TOOTH EXTRACTION</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>General disorders and administration site conditions</p> <p>ASTHENIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>4 / 11 (36.36%)</p> <p>occurrences (all)</p> <p>5</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>5 / 14 (35.71%)</p> <p>6</p>
<p>CHEST PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>FATIGUE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p>	<p>1 / 7 (14.29%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>MUCOSAL INFLAMMATION</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>0 / 11 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>OEDEMA</p>		

<p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>1 / 14 (7.14%)</p> <p>1</p>
<p>OEDEMA PERIPHERAL</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p>	<p>1 / 7 (14.29%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>PYREXIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>2 / 14 (14.29%)</p> <p>2</p>
<p>Immune system disorders</p> <p>CONTRAST MEDIA ALLERGY</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>1 / 14 (7.14%)</p> <p>1</p>
<p>SEASONAL ALLERGY</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>Reproductive system and breast disorders</p> <p>CYSTOCELE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p>	<p>1 / 7 (14.29%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>ERECTILE DYSFUNCTION</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p>
<p>UTERINE PROLAPSE</p> <p>alternative assessment type:</p>			

Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 1	0 / 14 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
COUGH alternative assessment type: Systematic subjects affected / exposed occurrences (all)	4 / 11 (36.36%) 5	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
DYSPHONIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
DYSPNOEA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 4	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
EPISTAXIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 7 (0.00%) 0	2 / 14 (14.29%) 3
OROPHARYNGEAL PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
PRODUCTIVE COUGH alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
RHINORRHOEA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
Psychiatric disorders			

IRRITABILITY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
Investigations			
ALANINE AMINOTRANSFERASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 3	0 / 7 (0.00%) 0	1 / 14 (7.14%) 2
AMYLASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 3	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
ASPARTATE AMINOTRANSFERASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 3	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
BLOOD ALKALINE PHOSPHATASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 3	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
BLOOD BILIRUBIN INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	1 / 7 (14.29%) 2	0 / 14 (0.00%) 0
BLOOD CREATININE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
BLOOD PRESSURE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	2 / 14 (14.29%) 3
EJECTION FRACTION DECREASED			

alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>GAMMA-GLUTAMYLTRANSFERASE INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 11 (18.18%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	8	0	0
<b>LIPASE INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
<b>PLATELET COUNT DECREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	3
<b>WEIGHT DECREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>WEIGHT INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>Injury, poisoning and procedural complications</b>			
<b>ANKLE FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>FALL</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>INCISION SITE PAIN</b>			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>RADIUS FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>Cardiac disorders</b>			
<b>BUNDLE BRANCH BLOCK RIGHT</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>CONGESTIVE CARDIOMYOPATHY</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>Nervous system disorders</b>			
<b>APHONIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>COMPLEX REGIONAL PAIN SYNDROME</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>DIZZINESS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>DYSAESTHESIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>DYSTONIA</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>FACIAL NEURALGIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>HEADACHE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 11 (27.27%)	1 / 7 (14.29%)	6 / 14 (42.86%)
occurrences (all)	5	1	7
<b>HYPOAESTHESIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>MIGRAINE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>MOVEMENT DISORDER</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>NERVOUS SYSTEM DISORDER</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>NEUROPATHY PERIPHERAL</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>NEUROTOXICITY</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0

<b>PARAESTHESIA</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
<b>PERIPHERAL SENSORY NEUROPATHY</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 1	0 / 14 (0.00%) 0
<b>SCIATICA</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
<b>SEIZURE</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
<b>SOMNOLENCE</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
<b>Blood and lymphatic system disorders</b> <b>ANAEMIA</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 1	1 / 14 (7.14%) 1
<b>LEUKOPENIA</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 3	0 / 14 (0.00%) 0
<b>NEUTROPENIA</b> alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 12	0 / 14 (0.00%) 0
<b>NEUTROPHILIA</b> alternative assessment type: Systematic			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>THROMBOCYTOPENIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p> <p>0 / 11 (0.00%)</p> <p>0</p>	<p>0 / 7 (0.00%)</p> <p>0</p> <p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p> <p>2 / 14 (14.29%)</p> <p>2</p>
<p>Ear and labyrinth disorders</p> <p>EAR PAIN</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>VERTIGO</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 11 (9.09%)</p> <p>1</p> <p>1 / 11 (9.09%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p> <p>0 / 7 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p> <p>0 / 14 (0.00%)</p> <p>0</p>
<p>Eye disorders</p> <p>CONJUNCTIVAL HAEMORRHAGE</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>LACRIMATION INCREASED</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>PERIORBITAL DISORDER</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>XEROPHTHALMIA</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 11 (0.00%)</p> <p>0</p> <p>1 / 11 (9.09%)</p> <p>1</p> <p>0 / 11 (0.00%)</p> <p>0</p> <p>1 / 11 (9.09%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p> <p>1 / 7 (14.29%)</p> <p>1</p> <p>0 / 7 (0.00%)</p> <p>0</p> <p>0 / 7 (0.00%)</p> <p>0</p>	<p>1 / 14 (7.14%)</p> <p>1</p> <p>0 / 14 (0.00%)</p> <p>0</p> <p>1 / 14 (7.14%)</p> <p>1</p> <p>0 / 14 (0.00%)</p> <p>0</p>
<p>Gastrointestinal disorders</p> <p>ABDOMINAL PAIN</p> <p>alternative assessment type: Systematic</p>			

subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	21	1	0
<b>ABDOMINAL PAIN UPPER</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>CHEILITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	3	0
<b>CONSTIPATION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>DENTAL CARIES</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	2	0
<b>DIARRHOEA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 11 (18.18%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	2
<b>DYSPEPSIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>GASTRITIS EROSIVE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>GINGIVAL BLEEDING</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2

MOUTH ULCERATION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
NAUSEA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
ORAL PAIN alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 1	0 / 14 (0.00%) 0
PEPTIC ULCER alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
STOMATITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 2	0 / 14 (0.00%) 0
TOOTHACHE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 7 (14.29%) 2	0 / 14 (0.00%) 0
VOMITING alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
Skin and subcutaneous tissue disorders ALOPECIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
ERYTHEMA alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
<b>ONYCHOLYSIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	1	4	0
<b>RASH</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>RASH MACULAR</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>SKIN SWELLING</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>Renal and urinary disorders</b>			
<b>PROTEINURIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 11 (54.55%)	2 / 7 (28.57%)	5 / 14 (35.71%)
occurrences (all)	55	5	15
<b>RENAL FAILURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>RENAL IMPAIRMENT</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
URINARY INCONTINENCE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 11 (18.18%)	1 / 7 (14.29%)	2 / 14 (14.29%)
occurrences (all)	2	1	2
BACK PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
MUSCLE SPASMS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 11 (18.18%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	6	0	0
MUSCULOSKELETAL DISCOMFORT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
MUSCULOSKELETAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 11 (36.36%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	7	0	0
MYALGIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
NECK PAIN			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
<b>OSTEOARTHRITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
<b>PAIN IN EXTREMITY</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
<b>PERIARTHRITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>SPINAL PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>Infections and infestations</b>			
<b>BACTERIURIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>BREAST DISCHARGE INFECTED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>BRONCHITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	1 / 14 (7.14%)
occurrences (all)	1	1	1
<b>CONJUNCTIVITIS</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
<b>CYSTITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
<b>DIVERTICULITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>EAR INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
<b>INFLUENZA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
<b>LACRIMAL GLAND ABSCESS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
<b>NAIL INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
<b>NASOPHARYNGITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 11 (9.09%)	1 / 7 (14.29%)	1 / 14 (7.14%)
occurrences (all)	3	1	1
<b>PERIODONTITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 11 (0.00%)	1 / 7 (14.29%)	0 / 14 (0.00%)
occurrences (all)	0	1	0

RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
RHINITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
SINUSITIS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
TOOTH ABSCESS alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
TOOTH INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 3	0 / 7 (0.00%) 0	1 / 14 (7.14%) 1
UPPER RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
URINARY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
VIRAL UPPER RESPIRATORY TRACT INFECTION alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2	0 / 7 (0.00%) 0	0 / 14 (0.00%) 0
Metabolism and nutrition disorders			

DECREASED APPETITE			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
GOUT			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
HYPERGLYCAEMIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
HYPOALBUMINAEMIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
HYPOCALCAEMIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
HYPOKALAEMIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
HYPONATRAEMIA			
alternative assessment type:			
Systematic			
subjects affected / exposed	2 / 11 (18.18%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
IRON DEFICIENCY			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 7 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Non-Squamous, Non-Small Cell Lung Cancer	Ovarian Cancer or Peritoneal Carcinoma	Renal Cell Carcinoma
-----------------------------------	--	--	-------------------------

Total subjects affected by non-serious adverse events subjects affected / exposed	12 / 16 (75.00%)	31 / 41 (75.61%)	6 / 6 (100.00%)
Vascular disorders			
<b>EMBOLISM VENOUS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>HYPERTENSION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	7 / 41 (17.07%)	2 / 6 (33.33%)
occurrences (all)	1	25	5
<b>LYMPHOEDEMA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Surgical and medical procedures			
<b>TOOTH EXTRACTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
<b>ASTHENIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 16 (18.75%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	5	5	0
<b>CHEST PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	3	0
<b>FATIGUE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	1	6	0
<b>MUCOSAL INFLAMMATION</b>			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 16 (6.25%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
<b>OEDEMA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>OEDEMA PERIPHERAL</b>			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 16 (12.50%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	3	7	0
<b>PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>PYREXIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
<b>Immune system disorders</b>			
<b>CONTRAST MEDIA ALLERGY</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>SEASONAL ALLERGY</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Reproductive system and breast disorders</b>			
<b>CYSTOCELE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>ERECTILE DYSFUNCTION</b>			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
UTERINE PROLAPSE			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	1 / 6 (16.67%)
occurrences (all)	0	2	1
DYSPHONIA			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
DYSPNOEA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EPISTAXIS			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 16 (12.50%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
OROPHARYNGEAL PAIN			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
PRODUCTIVE COUGH			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RHINORRHOEA			
alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Psychiatric disorders IRRITABILITY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
Investigations ALANINE AMINOTRANSFERASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 41 (4.88%) 2	0 / 6 (0.00%) 0
AMYLASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
ASPARTATE AMINOTRANSFERASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 41 (4.88%) 3	0 / 6 (0.00%) 0
BLOOD ALKALINE PHOSPHATASE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 41 (4.88%) 9	0 / 6 (0.00%) 0
BLOOD BILIRUBIN INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
BLOOD CREATININE INCREASED alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	5 / 41 (12.20%) 10	0 / 6 (0.00%) 0
BLOOD PRESSURE INCREASED alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>EJECTION FRACTION DECREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>GAMMA-GLUTAMYLTRANSFERASE INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>LIPASE INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>PLATELET COUNT DECREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>WEIGHT DECREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 16 (12.50%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
<b>WEIGHT INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>Injury, poisoning and procedural complications</b>			
<b>ANKLE FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>FALL</b>			
alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 41 (2.44%) 3	0 / 6 (0.00%) 0
<b>INCISION SITE PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>RADIUS FRACTURE</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>Cardiac disorders</b>			
<b>BUNDLE BRANCH BLOCK RIGHT</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>CONGESTIVE CARDIOMYOPATHY</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>Nervous system disorders</b>			
<b>APHONIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>COMPLEX REGIONAL PAIN SYNDROME</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>DIZZINESS</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	3 / 41 (7.32%) 3	0 / 6 (0.00%) 0
<b>DYSAESTHESIA</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>DYSTONIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>FACIAL NEURALGIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>HEADACHE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	1	6	0
<b>HYPOAESTHESIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
<b>MIGRAINE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>MOVEMENT DISORDER</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>NERVOUS SYSTEM DISORDER</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>NEUROPATHY PERIPHERAL</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

NEUROTOXICITY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
PARAESTHESIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 16 (12.50%) 2	2 / 41 (4.88%) 2	0 / 6 (0.00%) 0
PERIPHERAL SENSORY NEUROPATHY alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
SCIATICA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
SEIZURE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
SOMNOLENCE alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 41 (2.44%) 1	0 / 6 (0.00%) 0
Blood and lymphatic system disorders ANAEMIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	5 / 41 (12.20%) 20	0 / 6 (0.00%) 0
LEUKOPENIA alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	2 / 41 (4.88%) 7	0 / 6 (0.00%) 0
NEUTROPENIA alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	3 / 41 (7.32%) 9	0 / 6 (0.00%) 0
<b>NEUTROPHILIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>THROMBOCYTOPENIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	3 / 41 (7.32%) 10	0 / 6 (0.00%) 0
<b>Ear and labyrinth disorders</b>			
<b>EAR PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>VERTIGO</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>Eye disorders</b>			
<b>CONJUNCTIVAL HAEMORRHAGE</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>LACRIMATION INCREASED</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>PERIORBITAL DISORDER</b>			
alternative assessment type: Systematic			
subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 41 (0.00%) 0	0 / 6 (0.00%) 0
<b>XEROPHTHALMIA</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Gastrointestinal disorders</b>			
<b>ABDOMINAL PAIN</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 16 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
<b>ABDOMINAL PAIN UPPER</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>CHEILITIS</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>CONSTIPATION</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 16 (6.25%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
<b>DENTAL CARIES</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 16 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
<b>DIARRHOEA</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	0 / 16 (0.00%)	7 / 41 (17.07%)	0 / 6 (0.00%)
occurrences (all)	0	19	0
<b>DYSPEPSIA</b>			
alternative assessment type:			
Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>GASTRITIS EROSIVE</b>			
alternative assessment type:			
Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>GINGIVAL BLEEDING</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>MOUTH ULCERATION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>NAUSEA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 16 (18.75%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences (all)	7	8	0
<b>ORAL PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>PEPTIC ULCER</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>STOMATITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>TOOTHACHE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>VOMITING</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	5 / 41 (12.20%)	1 / 6 (16.67%)
occurrences (all)	0	5	1

<p>Skin and subcutaneous tissue disorders</p> <p><b>ALOPECIA</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 0 / 16 (0.00%)</p> <p>occurrences (all) 0</p> <p><b>ERYTHEMA</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 0 / 16 (0.00%)</p> <p>occurrences (all) 0</p> <p><b>ONYCHOLYSIS</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 0 / 16 (0.00%)</p> <p>occurrences (all) 0</p> <p><b>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 0 / 16 (0.00%)</p> <p>occurrences (all) 0</p> <p><b>RASH</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 2 / 16 (12.50%)</p> <p>occurrences (all) 3</p> <p><b>RASH MACULAR</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 1 / 16 (6.25%)</p> <p>occurrences (all) 1</p> <p><b>SKIN SWELLING</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 0 / 16 (0.00%)</p> <p>occurrences (all) 0</p>	<p>0 / 16 (0.00%)</p> <p>0</p> <p>2 / 16 (12.50%)</p> <p>3</p> <p>1 / 16 (6.25%)</p> <p>1</p> <p>0 / 16 (0.00%)</p> <p>0</p>	<p>0 / 41 (0.00%)</p> <p>0</p> <p>1 / 41 (2.44%)</p> <p>1</p> <p>0 / 41 (0.00%)</p> <p>0</p> <p>0 / 41 (0.00%)</p> <p>0</p>	<p>0 / 6 (0.00%)</p> <p>0</p>
<p>Renal and urinary disorders</p> <p><b>PROTEINURIA</b></p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed 8 / 16 (50.00%)</p> <p>occurrences (all) 26</p> <p><b>RENAL FAILURE</b></p>	<p>8 / 16 (50.00%)</p> <p>26</p>	<p>20 / 41 (48.78%)</p> <p>100</p>	<p>1 / 6 (16.67%)</p> <p>1</p>

alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>RENAL IMPAIRMENT</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
<b>URINARY INCONTINENCE</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>Musculoskeletal and connective tissue disorders</b>			
<b>ARTHRALGIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>BACK PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	5 / 41 (12.20%)	0 / 6 (0.00%)
occurrences (all)	0	5	0
<b>MUSCLE SPASMS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
<b>MUSCULOSKELETAL DISCOMFORT</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>MUSCULOSKELETAL PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	2	2	0
<b>MYALGIA</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
<b>NECK PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>OSTEOARTHRITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>PAIN IN EXTREMITY</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
<b>PERIARTHRITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>SPINAL PAIN</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
<b>Infections and infestations</b>			
<b>BACTERIURIA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>BREAST DISCHARGE INFECTED</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>BRONCHITIS</b>			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>CONJUNCTIVITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>CYSTITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>DIVERTICULITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>EAR INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
<b>INFLUENZA</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
<b>LACRIMAL GLAND ABSCESS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>NAIL INFECTION</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
<b>NASOPHARYNGITIS</b>			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

PERIODONTITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
RHINITIS			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SINUSITIS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
TOOTH ABSCESS			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
TOOTH INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 16 (6.25%)	2 / 41 (4.88%)	0 / 6 (0.00%)
occurrences (all)	1	4	0
URINARY TRACT INFECTION			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	9 / 41 (21.95%)	1 / 6 (16.67%)
occurrences (all)	0	26	1
VIRAL UPPER RESPIRATORY TRACT INFECTION			
alternative assessment type: Systematic			

subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
DECREASED APPETITE			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 16 (12.50%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	2	4	0
GOUT			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERGLYCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	3 / 41 (7.32%)	0 / 6 (0.00%)
occurrences (all)	0	15	0
HYPOALBUMINAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	4 / 41 (9.76%)	0 / 6 (0.00%)
occurrences (all)	0	11	0
HYPOCALCAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
HYPOKALAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPONATRAEMIA			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 16 (0.00%)	1 / 41 (2.44%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
IRON DEFICIENCY			
alternative assessment type: Systematic			

subjects affected / exposed	1 / 16 (6.25%)	0 / 41 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 February 2013	Major changes included a change to study personnel and clarification of study phase.
08 November 2018	Changes to provide for transition of patients from supply of bevacizumab via this clinical study to commercial and Post-Trial Access Program supplies

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported